cation of rheumatoid arthritis, polyarticular-course juvenile idiopathic arthritis, and systemic-onset juvenile idiopathic arthritis. Overseas, Actemra was approved in the European Union in January 2009 (European product name: RoActemra). R1594: R1594 is a second-generation humanized anti-CD20 monoclonal antibody that binds to a particular protein (the CD20 antigen) on the surface of human B cell lymphocytes, activating the immune system to eliminate the marked cells. R1594 is being studied for various autoimmune diseases by Roche Group companies. Japan is participating in an ongoing global phase III study of R1594 for rheumatoid arthritis. OTHER FIELDS Chronic Hepatitis C Pegasys/Copegus: Pegasys (generic name: peginterferon alfa-2a) enables sustained therapeutic concentrations to be achieved with once-weekly administration. Copegus (generic name: ribavirin) is a chronic hepatitis C treatment that synergistically improves the antiviral effect when used in combination with interferon. The company has obtained approval for Copegus and launched it in combination with Pegasys for the treatment of patients with chronic hepatitis C serogroup 1 infection and high viral load, or those who have either not responded to, or have relapsed following, interferon monotherapy. It offers peginterferon for both monotherapy and combination therapy. NA808: NA808 is a small-molecule compound that is intended to prove effective as a treatment for chronic hepatitis C. The drug acts on the body, not the virus, to inhibit the growth of the virus. Influenza Tamiflu: Tamiflu is an oral anti-influenza agent that is used against both type A and type B infections. It inhibits viral replication by binding to and blocking the action of neuraminidase, an enzyme essential for the multiplication of the influenza virus. Angina Pectoris Sigmart: Anti-anginal agent Sigmart is a drug that overcomes the flaws of nitric acid compounds, such as nitroglycerin and treats various types of angina pectoris. Castleman’s Disease Actemra: Actemra is a humanized anti-human IL-6 receptor monoclonal antibody produced using genetical recombination technology. With a mechanism of action that inhibits the receptor for IL-6, a type of cytokine, the drug improves Castleman’s disease symptoms. Diabetes R1583 (ITM-077): R1583 is a new compound that mimics GLP-1 (glucagon-like peptide 1), a hormone that stimulates the secretion of insulin. As GLP-1 stimulates insulin secretion when blood sugar levels are too high, there is little risk of the drug causing low blood sugar. R1583 is formulated using technology from Ipsen that enables maintenance of therapeutic concentrations for extended periods. R1583 is being co-developed in Japan with Teijin Pharma Limited. CSG452 (R7201): An oral preparation that reduces blood sugar level, CSG453 is intended for the treatment for type 2 diabetes. The company has licensed the drug to Roche and conducting phase I domestic clinical trials. R1579: R1579 is a dipeptidyl peptidase-IV (DPP-IV) inhibitor licensed from Roche. The company is conducting phase I domestic clinical trials for the treatment of type 2 diabetes. Schizophrenia R1678: R1678, a small-molecule compound licensed from Roche, is intended for the treatment of schizophrenia. The company is conducting global phase II clinical trials. History Chugai Pharmaceutical Co., Ltd. was founded in 1925.
chugai pharmaceutical co ltd
(4519:Tokyo Stock Exchange)
1-1 Nihonbashi-Muromachi 2-Chome
Phone: 81 3 3281 6611
Fax: 81 3 3281 6607www.chugai-pharm.co.jp
|AbbVie Inc||$55.82 USD||+0.69|
|Eli Lilly & Co||$87.52 USD||+2.34|
|Merck KGaA||€77.45 EUR||-0.202|
|Teva Pharmaceutical Industries Ltd||$60.06 USD||+1.56|
|View Industry Companies|
Sponsored Financial Commentaries
To contact CHUGAI PHARMACEUTICAL CO LTD, please visit www.chugai-pharm.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.